A NEW PHARMACEUTICAL COMBINATION COMPRISING AN ANTICANCER DRUG PACLITAXEL AND BIOACTIVE BIOENHANCER PIPERINE FOR ENHANCING BIOAVAILABILITY OF PACLITAXEL
The present invention relates to a bioenhancing/bioavailability-facilitating composition comprising an anticancer drug paclitaxel and bioactive bioaenhancer piperine. Oral bioavailability of paclitaxel is low because of induction of P-glycoprotein and cytochrome P-3A4. Piperine inhibits the action mediated by P-glycoprotein and cytochrome P-3A4. The combination is characterized in having clinically significant increased bioavailability when compared to paclitaxel alone. Enhanced bioavailability of Paclitaxel results in the reduction of both dosages and dose-related side effects. Thus without resorting to the prodrug method a new pharmaceutical composition comprising piperine and paclitaxel with significant increase in bioavailability of paclitaxel is herein disclosed.